Ginkgo Bioworks Holdings, Inc. (DNA) fundamentals score
Its mission is to make biology easier to engineer. That has never changed. Every choice Ginkgo Bioworks Holdings has made with respect to its business model, its platform, its people, and its culture is grounded in whether it will advance its mission.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NYSE
Overall: 3.3 out of 10, Unhealthy fundamentals
- Growth: 2.2/10
- Profitability: 1.0/10
- Financial health: 5.2/10
- Earnings quality: 6.9/10
- Valuation: 2.7/10
Scores are calculated from Ginkgo Bioworks Holdings, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10